Latest Breaking News On - Largest efficacy - Page 1 : comparemela.com

Bharat Biotech concludes Covaxin's final analysis; claims 77.8% efficacy in phase-3 trial

Bharat Biotech concludes Covaxin s final analysis; claims 77.8% efficacy in phase-3 trial Sharing the final phase-3 pre-print data on medRxiv, Bharat Biotech claimed that Covaxin provides 65.2% protection against the Delta variant, which is currently the dominant COVID-19 strain in India Bharat Biotech on Saturday announced that Covaxin has been found to be 77.8% effective against symptomatic COVID-19 BusinessToday.In Updated Jul 03, 2021, 8:42 AM IST Bharat Biotech said early on Saturday that it has concluded the final analysis for its COVID-19 vaccine Covaxin as part of phase-3 clinical trials. Sharing the final phase-3 pre-print data on medRxiv, the Hyderabad-based pharma company claimed that its indigenous jab demonstrates an overall efficacy of 77.8% against symptomatic infection.

IndiaHyderabadAndhra pradeshBharatBharat biotechLargest efficacyPrint data publishedஇந்தியாஹைதராபாத்ஆந்திரா பிரதேஷ்பாரத்பாரத் பயோடெக்

Coronavirus: Covaxin Overall 77.8% Effective, Claims Bharat Biotech In Final Phase 3 Data

Covaxin has received emergency use authorizations in 16 countries, Bharat Biotech said. Highlights The vaccine offers 65.2 per cent protection against Delta variant Phase 3 trials were conducted on 130 symptomatic Covid patients New Delhi: Bharat Biotech s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed. The vaccine offers 65.2 per cent protection , it said, against the rapidly emerging Delta variant. It was also found to be 93.4 per cent effective against severe symptomatic COVID-19, the company said. Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune.

MexicoPhilippinesHyderabadAndhra pradeshIndiaIranPuneMaharashtraBrazilBharatBharat biotechKrishna ellaBalram bhargavaSuchitra ellaIndian council of medical researchDepartment of health research

Phase 3 trial: Covaxin 77.8% effective against symptomatic COVID-19, 65.2% against Delta Variant

Phase 3 trial: Covaxin 77.8% effective against symptomatic COVID-19, 65.2% against Delta Variant The vaccine demonstrated 93.4% efficacy against severe symptomatic cases company said. The results are based on the evaluation of 130 confirmed cases. (Image Source: Reuters) Updated: Jul 3, 2021, 11:11 AM IST Hyderabad-based Bharat biotech s Covaxin has been found to be 77.8% effective against symptomatic COVID-19 in its phase 3 clinical trials. It also showed 65.2% efficacy against the Delta Plus variant. The results are based on the evaluation of 130 confirmed cases. The indigenously developed vaccine demonstrated 93.4% efficacy against severe symptomatic COVID-19, the company claimed. The safety analysis demonstrated that adverse events reported post-vaccination were similar for Covaxin and the placebo. Twelve percent of subjects experienced commonly known side effects and less than 0.5% of subjects felt serious adverse events.

IndiaPuneMaharashtraBharatBharat biotechHyderabad based bharatDelta plusLargest efficacyPrint data publishedஇந்தியாபுனேமகாராஷ்டிராபாரத்பாரத் பயோடெக்ஹைதராபாத் அடிப்படையிலானது பாரத்டெல்டா ப்லஸ்

Covaxin tiene eficacia del 77.8% y es efectiva contra variantes: laboratorio

Covaxin tiene eficacia del 77.8% y es efectiva contra variantes: laboratorio
sinembargo.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sinembargo.mx Daily Mail and Mail on Sunday newspapers.

IndiaNew delhiDelhiBrazilBharatBalram bhargavaTwitterIndian councilIndian council of medicalProven safeLargest efficacyDates back publishedBharat biotechஇந்தியாபுதியது டெல்ஹிடெல்ஹி

Covaxin tienen una eficacia del 77.8 % y protege de todas las variantes

Covaxin tienen una eficacia del 77.8 % y protege de todas las variantes
periodicocentral.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from periodicocentral.mx Daily Mail and Mail on Sunday newspapers.

IndiaBrazilBharatBalram bhargavaTwitterIndian councilIndian council of medicalProven safeLargest efficacyDates back publishedBharat biotechஇந்தியாபிரேசில்பாரத்பால்ராம் பார்கவாட்விட்டர்